biotech / news / / Barchart
Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on developing and commercializing innovative therapies.
The FDA approved expanded use of ALYFTREK and TRIKAFTA for more cystic fibrosis patients.
KEY POINTS
- Expanded eligibility now covers about 95% of U.S. cystic fibrosis patients, adding 800 new candidates.
- Analysts expect Vertex's Q1 2026 adjusted EPS to rise 9.3% year-over-year to $3.88.
- Despite strong analyst ratings, Vertex shares have underperformed the S&P 500 and healthcare sector ETF.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →